StockSelector.com
  Research, Select, & Monitor Thursday, July 18, 2019 7:21:39 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Hemispherx BioPharma, Inc.$4.05($.02)(.49%)

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  Hemispherx BioPharma, Inc. vs Drugs Wholesale

Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection and the experimental therapeutics Ampligen and Oragens. Alferon N Injection is approved for a category of STD infection, and Ampligen and Oragens represent a large portfolio experimental RNA nucleic acids being developed for globally important viral diseases, severely debilitating disorders and biodefense applications. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. The Company is actively engaged in further expansion of its intellectual property on a world wide basis to reflect the global distribution of the various disorders which its platform technologies address.




While most of the companies below engage in the sale of prescription (name brand and generic) pharmaceuticals to retailers, many of them engage in much more. Some do their own research, development, and marketing of new drugs on the market. Others have their hands out of drugs, but in semi-related fields. They may provide health and beauty aid products, fragrances, cosmetics, packaged food, vitamins, herbal supplements, and even gloves, children's and periodical publications.
 Totals Company Industry
  Sales: $0.4 Mil $416,718.4 Mil
  Market Cap: $207.2 Mil $486,347.2 Mil
  Analysts Recommendation: N/A Buy

 Averages Company Industry
 Growth
  Historic Revenue: (15.9%) 30.4%
  Estimated Revenue: N/A 7.7%
  Historic Earnings: N/A 6.9%
  Estimated Earnings: N/A 14.6%
  Stock Price (1 Year): (70.2%) (21.5%)
  Cash per Share: (85.9%) (17.5%)
  Dividend: N/A N/A
 Price
  Trailing PE: N/A N/A
  Forward PE: N/A 14.1
  Price-to-Sales: 667.2 N/A
  Price-to-Book: .9 2.3
  Dividend Yield: N/A N/A
  Market Cap: $207.2 Mil $34,739.1 Mil
  Operations
  Net Margin: (3,365.9%) (773.6%)
  Gross Margin: (140.5%) 37.6%
  Return on Equity: (1.9) (.0)
  Return on Assets: (.7) (.1)
  Balance Sheet
  Current Ratio: .7 1.4
  Quick Ratio: .7 .9
  Cash Ratio: .3 .5
  Debt-to-Equity: 1.7 1.7
  Interest Coverage: 4.4 .1
 Technicals
  Relative-Strength Index: 46.1 N/A

 Other companies in Drugs Wholesale Price Market Cap
  Nestlé  (NSRGY) $104.60 $320,389.8 Mil
  Unilever, PLC  (UL) $63.10 $73,734.2 Mil
  McKesson Corp.  (MCK) $138.63 $26,593.4 Mil
  Associated British Foods Plc  (ASBFY) $28.60 $22,641.8 Mil
  Cardinal Health, Inc.  (CAH) $45.07 $13,433.6 Mil






Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2019 StockSelector.com. All rights reserved.